| MeSH term | MeSH ID | Detail |
|---|---|---|
| Hyperplasia | D006965 | 34 associated lipids |
| Leukemia | D007938 | 74 associated lipids |
| Leukemia, Myeloid | D007951 | 52 associated lipids |
| Bronchial Spasm | D001986 | 18 associated lipids |
| Lymphoma, B-Cell | D016393 | 24 associated lipids |
| Asthenia | D001247 | 5 associated lipids |
| Hypopharyngeal Neoplasms | D007012 | 1 associated lipids |
MAYTANSINE
MAYTANSINE is a lipid of Polyketides (PK) class. Maytansine is associated with abnormalities such as Myelosuppression and BOSLEY-SALIH-ALORAINY SYNDROME. The involved functions are known as Mutation, Agent, Polymerization, Cell Cycle Arrest and Drug Kinetics. Maytansine often locates in Cytoplasm, Hepatic, Lysosomes, Cell surface and Microtubules. The associated genes with MAYTANSINE are ABCB1 gene, HM13 gene, CNN1 gene, CYP2C8 gene and CYP2D6 gene. The related lipids are Valerates. The related experimental models are Xenograft Model.
Cross Reference
Introduction
To understand associated biological information of MAYTANSINE, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with MAYTANSINE?
MAYTANSINE is suspected in Myelosuppression, BOSLEY-SALIH-ALORAINY SYNDROME and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with MAYTANSINE
PubChem Associated disorders and diseases
What pathways are associated with MAYTANSINE
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with MAYTANSINE?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with MAYTANSINE?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with MAYTANSINE?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with MAYTANSINE?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with MAYTANSINE?
Xenograft Model
Xenograft Model are used in the study 'IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.' (Ab O et al., 2015).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with MAYTANSINE
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Mugera GM and Ward JM | Acute toxicity of maytansine in F344 rats. | 1977 | Cancer Treat Rep | pmid:563288 |
| Eagan RT et al. | Phase II evaluation of maytansine in patients with metastatic lung cancer. | 1978 | Cancer Treat Rep | pmid:709559 |
| Cabanillas F et al. | Phase I study of maytansine using a 3-day schedule. | 1978 | Cancer Treat Rep | pmid:348310 |
| Chabner BA et al. | Initial clinical trials of maytansine, an antitumor plant alkaloid. | 1978 | Cancer Treat Rep | pmid:348311 |
| Blum RH and Kahlert T | Maytansine: a phase I study of an ansa macrolide with antitumor activity. | 1978 | Cancer Treat Rep | pmid:348312 |
| deVere White R et al. | Maytansine as a cause of acute proliferative disorder of bladder urothelium in the rat. | 1983 | Cancer Treat Rep | pmid:6825127 |
| Edmonson JH et al. | Phase II study of maytansine in advanced sarcomas. | 1983 | Cancer Treat Rep | pmid:6850657 |
| Ratanatharathorn V et al. | Phase II evaluation of maytansine in refractory non-Hodgkin's lymphoma: a Southwest Oncology Group study. | 1982 | Cancer Treat Rep | pmid:7093975 |
| Edmonson JH et al. | Phase II study of maytansine in advanced breast cancer. | 1981 May-Jun | Cancer Treat Rep | pmid:7237478 |
| Neidhart JA et al. | Minimal single-agent activity of maytansine in refractory breast cancer: a Southwest Oncology Group study. | 1980 Apr-May | Cancer Treat Rep | pmid:7427953 |
| Sabio H et al. | Maytansine in refractory childhood acute lymphocytic leukemia: a Pediatric Oncology Group study. | 1983 | Cancer Treat Rep | pmid:6580069 |
| Phase II trials of maytansine, low-dose chlorozotocin, and high-dose chlorozotocin as single agents against advanced measurable adenocarcinoma of the pancreas. Gastrointestinal Tumor Study Group. | 1985 | Cancer Treat Rep | pmid:2859924 | |
| Issell BF and Crooke ST | Maytansine. | 1978 | Cancer Treat. Rev. | pmid:367597 |
| Kümler I et al. | A systematic review of dual targeting in HER2-positive breast cancer. | 2014 | Cancer Treat. Rev. | pmid:24080156 |
| Yan M et al. | HER2 aberrations in cancer: implications for therapy. | 2014 | Cancer Treat. Rev. | pmid:24656976 |
| Carneiro BA et al. | Emerging therapeutic targets in bladder cancer. | 2015 | Cancer Treat. Rev. | pmid:25498841 |
| Stebbings H and van Bueren J | Stability of microtubules from insect ovarioles. | 1981 | Cell Biol. Int. Rep. | pmid:7273149 |
| Diessner J et al. | Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1). | 2014 | Cell Death Dis | pmid:24675467 |
| David B et al. | Rhazinilam mimics the cellular effects of taxol by different mechanisms of action. | 1994 | Cell Motil. Cytoskeleton | pmid:7954858 |
| Zhao P et al. | Amide N-glycosylation by Asm25, an N-glycosyltransferase of ansamitocins. | 2008 | Chem. Biol. | pmid:18721757 |
| Li Y et al. | Dual carbamoylations on the polyketide and glycosyl moiety by asm21 result in extended ansamitocin biosynthesis. | 2011 | Chem. Biol. | pmid:22195559 |
| Wang H et al. | Albumin nanoparticle encapsulation of potent cytotoxic therapeutics shows sustained drug release and alleviates cancer drug toxicity. | 2017 | Chem. Commun. (Camb.) | pmid:28195282 |
| Fishkin N et al. | A novel pathway for maytansinoid release from thioether linked antibody-drug conjugates (ADCs) under oxidative conditions. | 2011 | Chem. Commun. (Camb.) | pmid:21874179 |
| Akimoto H et al. | Chemical modification of ansamitocins. II. Synthesis of 3-epimaytansionoids via 3-maytansinones. | 1984 | Chem. Pharm. Bull. | pmid:6437689 |
| Kawai A et al. | Chemical modification of ansamitocins. III. Synthesis and biological effects of 3-acyl esters of maytansinol. | 1984 | Chem. Pharm. Bull. | pmid:6441645 |
| Cassady JM et al. | Recent developments in the maytansinoid antitumor agents. | 2004 | Chem. Pharm. Bull. | pmid:14709862 |
| Wu Y et al. | N-methylation of the amide bond by methyltransferase asm10 in ansamitocin biosynthesis. | 2011 | Chembiochem | pmid:21681880 |
| Harmrolfs K et al. | Cyclization of synthetic seco-proansamitocins to ansamitocin macrolactams by Actinosynnema pretiosum as biocatalyst. | 2010 | Chembiochem | pmid:21077088 |
| Taft F et al. | Highly active ansamitocin derivatives: mutasynthesis using an AHBA-blocked mutant. | 2008 | Chembiochem | pmid:18381586 |
| Kubota T et al. | Determination of the cryptic stereochemistry of the first PKS chain-extension step in ansamitocin biosynthesis by Actinosynnema pretiosum. | 2006 | Chembiochem | pmid:16927319 |
| Knobloch T et al. | Mutational biosynthesis of ansamitocin antibiotics: a diversity-oriented approach to exploit biosynthetic flexibility. | 2011 | Chembiochem | pmid:22238146 |
| Seidel K et al. | Synthesis of Magnetic-Nanoparticle/Ansamitocin Conjugates-Inductive Heating Leads to Decreased Cell Proliferation In Vitro and Attenuation Of Tumour Growth In Vivo. | 2017 | Chemistry | pmid:28585348 |
| Wang LL et al. | A Bio-Chemosynthetic Approach to Superparamagnetic Iron Oxide-Ansamitocin Conjugates for Use in Magnetic Drug Targeting. | 2017 | Chemistry | pmid:27935144 |
| Mancuso L et al. | Preparation of thermocleavable conjugates based on ansamitocin and superparamagnetic nanostructured particles by a chemobiosynthetic approach. | 2014 | Chemistry | pmid:25346489 |
| Taft F et al. | Combined muta- and semisynthesis: a powerful synthetic hybrid approach to access target specific antitumor agents based on ansamitocin P3. | 2012 | Chemistry | pmid:22170289 |
| Kwon Y et al. | Telangiectasia and Pulmonary Arterial Hypertension Following Treatment With Trastuzumab Emtansine: A Case Report. | 2016 | Chest | pmid:27055712 |
| Bertholjotti I | [Antibody-drug conjugate--a new age for personalized cancer treatment]. | 2011 | Chimia (Aarau) | pmid:22026193 |
| Gligorov J et al. | Emilia: use cunning to survive cancer. | 2018 | Chin Clin Oncol | pmid:29307196 |
| Ricci F and Le Tourneau C | Trastuzumab emtansine in HER2-positive metastatic breast cancer: what is the best sequence? | 2018 | Chin Clin Oncol | pmid:29156892 |
| Bander NH et al. | Antibody-drug conjugate technology development for hematologic disorders. | 2012 | Clin Adv Hematol Oncol | pmid:23072775 |
| Piwko C et al. | Safety Profile and Costs of Related Adverse Events of Trastuzumab Emtansine for the Treatment of HER2-Positive Locally Advanced or Metastatic Breast Cancer Compared to Capecitabine Plus Lapatinib from the Perspective of the Canadian Health-Care System. | 2015 | Clin Drug Investig | pmid:26123628 |
| Bourdeanu L and Luu T | Nursing perspectives on trastuzumab emtansine for the treatment of metastatic breast cancer. | 2013 | Clin J Oncol Nurs | pmid:24080060 |
| Ohashi K et al. | Trastuzumab Emtansine in HER2+ Recurrent Metastatic Non-Small-Cell Lung Cancer: Study Protocol. | 2017 | Clin Lung Cancer | pmid:27497829 |
| Socinski MA et al. | Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Patients With Extensive-Stage Disease. | 2017 | Clin Lung Cancer | pmid:28341109 |
| Kantarjian HM et al. | A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia. | 2016 | Clin Lymphoma Myeloma Leuk | pmid:26775883 |
| Li C et al. | A Phase I Pharmacokinetic Study of Trastuzumab Emtansine (T-DM1) in Patients with Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function. | 2017 | Clin Pharmacokinet | pmid:27995530 |
| Lu D et al. | An integrated multiple-analyte pharmacokinetic model to characterize trastuzumab emtansine (T-DM1) clearance pathways and to evaluate reduced pharmacokinetic sampling in patients with HER2-positive metastatic breast cancer. | 2013 | Clin Pharmacokinet | pmid:23553425 |
| Kalsi R et al. | Brain metastasis and response to ado-trastuzumab emtansine: a case report and literature review. | 2015 | Clin. Breast Cancer | pmid:25454740 |
| Menderes G et al. | SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression. | 2017 | Clin. Cancer Res. | pmid:28679774 |
| Blanc V et al. | SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies. | 2011 | Clin. Cancer Res. | pmid:22003072 |